BIND Therapeutics (BIND) Shares are Up 54.26%

BIND Therapeutics (BIND) : Traders are bullish on BIND Therapeutics (BIND) as it has outperformed the S&P 500 by a wide margin of 89.97% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 54.37%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 54.26% in the last 1 week, and is up 96.36% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 33.13% and the 50-Day Moving Average is 60.21%. BIND Therapeutics, Inc. has dropped 46.1% during the last 3-month period . Year-to-Date the stock performance stands at -65.87%.


BIND Therapeutics (NASDAQ:BIND): On Fridays trading session , Opening price of the stock was $0.77 with an intraday high of $0.8274. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $0.69. However, the stock managed to close at $0.7815, a loss of 10.17% for the day. On the previous day, the stock had closed at $0.87. The total traded volume of the day was 2,474,776 shares.

BIND Therapeutics, Inc. is a clinical-stage nano-medicine platform company. The Company is engaged in developing a pipeline of Accurins. The Company utilizes its Medicinal Nano-engineering platform to develop a pipeline of Accurins in oncology. The Companys products include BIND-014 and BIND-510. The Companys lead drug candidate BIND-014 is a prostate-specific membrane antigen (PSMA)-targeted Accurin that contains docetaxel, a clinically validated cancer chemotherapy drug. PSMA is a clinically validated tumor marker expressed on prostate cancer cells and the blood vessels of many types of non-prostate solid tumors. It has completed a Phase I clinical trial evaluating BIND-014 in patients with advanced and metastatic solid tumors. The Companys product candidate BIND-510 is also a PSMA-targeted Accurin containing vincristine. BIND-510 is designed to concentrate high levels of vincristine in tumors while limiting exposure to healthy tissue.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *